View Future GrowthEnhanced Group 과거 순이익 실적과거 기준 점검 0/6Enhanced Group의 수입은 연평균 -418.7%의 비율로 감소해 온 반면, Specialty Retail 산업의 수입은 연간 3.5% 감소했습니다.핵심 정보-418.74%순이익 성장률-410.38%주당순이익(EPS) 성장률Specialty Retail 산업 성장률4.13%매출 성장률n/a자기자본이익률n/a순이익률-1,444,024.97%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.공시 • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Enhanced Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이MUN:K7J 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-4040031 Dec 250-2727030 Sep 250-1414031 Dec 240-540양질의 수익: K7J 은(는) 현재 수익성이 없습니다.이익 마진 증가: K7J는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 K7J의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 K7J의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: K7J은 수익성이 없어 지난 해 수익 성장률을 Specialty Retail 업계(-2.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: K7J의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YRetail 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 01:49종가2026/07/01 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Enhanced Group Inc.는 3명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matthew AbrahamBerenbergSusan AndersonCanaccord GenuityAlex FuhrmanLucid Capital Markets
공시 • Jun 30Enhanced Launches the Thor Protocol Product Stack on Its Live Enhanced PlatformEnhanced had announced the launch of its Thor Protocol, a comprehensive, clinician-supervised performance product stack available exclusively through its Live Enhanced consumer platform. The Thor Protocol is designed to help consumers support their strength, recovery, and physical performance under the guidance of licensed clinicians. The stack reflects the same evidence-based, medically supervised philosophy that has defined Enhanced's approach to elite athlete performance. Thor’s Protocol includes three clinician-prescribed products, each personalized to the individual’s lab results and health profile. Testosterone levels decline with age. Published research shows that clinician-supervised testosterone therapy helps support lean body composition, energy, and vitality in men that qualify. Long-term data show favorable effects on body composition, mood, and metabolic markers when levels are maintained within the physiological range. Thor’s protocol starts with baseline bloodwork, with dosing matched to individual needs and monitored over time. NAD+ is a coenzyme central to cellular energy metabolism. Levels decline naturally with age, and research suggests that supporting NAD+ levels helps support cellular energy production and healthy aging. A 2025 study in Nature detailed NAD+’s role in mitochondrial function and cellular resilience, and preclinical research has shown that restoring NAD+ levels supports energy production and supports markers associated with healthy aging. The Enhanced NAD+ protocol is clinician-supervised, with dosage matched to the individual. Daily low-dose tadalafil supports healthy blood flow by promoting nitric oxide-mediated vasodilation. Clinical research supports improvements in endothelial function and vascular tone, with trials reporting better circulation and improved endothelial function. The protocol is clinician-supervised with daily dosing personalized to the individual. For strength athletes, the problem isn’t one system slowing down. It’s multiple systems declining at the same time: hormonal output, cellular energy, vascular function. Thor’s Protocol is intended to address these areas through individualized clinician-guided treatment. Testosterone supports the hormonal foundation. NAD+ supports cellular energy production and recovery at the mitochondrial level. Tadalafil supports blood flow and vascular function. Individually, each addresses a real gap. Together, the protocol addresses multiple physiological systems through individualized clinician-guided care. Every protocol starts with a clinician review by a licensed clinician through Enhanced’s healthcare provider partners. Every protocol is monitored over time, and adjusted as the individual’s data changes. This is not a one-size-fits-all stack off a shelf. It’s a clinician-guided protocol matched to the consumer's physiology. Thor's Protocol is available now exclusively through the Live Enhanced platform. Clinician-prescribed products require a consultation with a licensed provider through the platform.
Board Change • Jun 29Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Director Jim Simpson is the most experienced director on the board, commencing their role in 2026. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jun 15Enhanced Group Inc. announced that it expects to receive $49.999991 million in funding from Apeiron Investment Group LimitedEnhanced Group Inc. announced that it has entered into an agreement to issue 12,853,468 shares of its Class A common stock (the "Common Stock") at a purchase price per share equal to $3.89 per share and 12,853,468 warrants to purchase Common Stock with an exercise price of $3.89 per share for the gross proceeds of $50 million. The initial tranche of the PIPE is expected to close on or about June 17, 2026 with the remaining two tranches in aggregate expected to close within forty-five days of the initial closing, in each case subject to satisfaction of customary closing conditions. The Private Placement is expected to close in three tranches, with approximately $25.0 million of the gross proceeds expected to close on or about June 17, 2026 (the “First Closing”), approximately $11.75 million of the gross proceeds expected to close on or about June 22, 2026 and the remaining approximately $13.25 million of the gross proceeds in third tranche. The transaction involves participation of Apeiron Investment Group Limited and Maximilian Martin, Chief Executive Officer of the Company and a member of the Board of Directors of the Company as an investors.
공시 • May 22Enhanced Group, Inc. Provides Clinical Trial Update for Enhanced Medical ProgramEnhanced, announced that its Institutional Review Board (IRB) approved clinical study has been posted for review to ClinicalTrials.gov. The study is part of the Enhanced Medical Program, which gives athletes the opportunity to consider FDA-approved substances, prescribed by doctors as part of the study, and continuous medical screenings to explore enhancements in the safest possible manner. The interventional phase of the trial has now concluded, with the five-year observational monitoring period now commencing. The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue. With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in Las Vegas, the company also announced preliminary details regarding approved substance usage by athletes during the 12-week trial period. The company will not be commenting further on these aggregate totals until the scheduled Enhanced Games press conference on Saturday May 23rd (1:15pm PST) before the approximately 200 credentialed media from 20 different countries who are expected in attendance. The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under U.S. Food & Drug Administration (FDA) guidelines were studied. No peptides currently on the FDA's Category 2 banned list were included in the research. With the interventional period now concluded, Enhanced is releasing aggregate information reflecting the substances incorporated into each athlete's personalized protocols. Individual athlete protocols will not be made publicly available by Enhanced. According to aggregate data collected in the lead up to the Games: 91% of athletes used testosterone or testosterone esters; 79% of athletes used human growth hormone (hGH); 62% of athletes used stimulants (eg. Adderall); 50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols; 41% of athletes used erythropoietin (EPO); 29% of athletes used an anabolic steroid agent (eg. Deca durabolin); 5% of athletes used hormonal support therapies (eg. hCG). The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples. All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.
Board Change • May 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Jim Murren was the last independent director to join the board, commencing their role in 2026. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.